Table 3.
The percentages of patients are shown according to obesity, smoking, psychiatric disease, joint involvement and pruritus (percentages related to the switching of drugs are also shown in the table).
| OBESITY | SWITCH | SMOKING | PHSYCHIATRIC DISEASE | JOINT INVOLVEMENT | PRURITIS | |
|---|---|---|---|---|---|---|
| TOTAL (BIOLOGIC) | 28.6% (N=65) | 23.7% (N=77) | 53.6% (N=119) | 16.7% (N=37) | 31.9% (N=71) | 77.0% (N=171) |
| ADALIMUMAB | 25.6% (N=10) | 17.9% (N=7) | 53.8% (N=21) | 15.4% (N=6) | 34.2% (N=13) | 74.4% (N=29) |
| ETANERCEPT | 20.0% (N=2) | 20.0% (N=2) | 50.0% (N=5) | 0.0% (N=0) | 44.4% (N=4) | 70.0% (N=7) |
| INFLIXIMAB | 28.6% (N=4) | 21.4% (N=3) | 57.1% (N=8) | 21.4% (N=3) | 42.9% (N=6) | 92.9% (N=13) |
| SERTOLIZUMAB | 40.0% (N=4) | 40.0% (N=4) | 40.0% (N=4) | 10.0% (N=1) | 57.1% (N=4) | 70.0% (N=7) |
| USTEKINUMAB | 30.4% (N=17) | 17.9% (N=10) | 64.3% (N=36) | 14.3% (N=8) | 26.5% (N=13) | 73.2% (N=41) |
| SECUKINUMAB | 32.2% (N=19) | 52.5% (N=31) | 47.5% (N=28) | 23.7% (N=14) | 38.0% (N=19) | 78.0% (N=46) |
| IXEKIZUMAB | 31.3% (N=5) | 50.0% (N=8) | 50.0% (N=8) | 6.3% (N=1) | 28.6% (N=4) | 81.3% (N=13) |
| RISANKIZUMAB | 20.0% (N=2) | 60.0% (N=4) | 40.0% (N=4) | 10.0% (N=1) | 40.0% (N=4) | 90.0% (N=9) |
| GUSELKUMAB | 25.0% (N=2) | 75.0% (N=6) | 62.5% (N=5) | 37.5% (N=3) | 57.1% (N=4) | 75.0% (N=6) |
| TOTAL (CONVENTIONAL) | 27.2% (N=28) | ----------- | 54.4% (N=) | 22.3% (N=23) | 17.4% (N=18) | 81.5% (N=103) |
| METHOTREXATE | 31.6% (N=18) | ----------- | 54.4% (N=31) | 21.1% (N=12) | 17.5% (N=10) | 82.5% (N=47) |
| ACITRETIN | 21.7% (N=10) | ----------- | 58.7% (N=27) | 23.9% (N=11) | 17.4% (N=8) | 80.4% (N=37) |